Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production.

2026-01-14

Korean biotech firms aim to expand U.S. presence at J.P. Morgan Healthcare Conference

At the 44th J.P. Morgan Healthcare Conference, Korean biotech firms are making efforts to enhance their presence in the U.S. market.

2026-01-13

At J.P. Morgan Healthcare Conference, Korean pharmaceuticals set to share strategies, seal deals

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and up-and-comers, from featured presentations to deal making.

2025-01-14

Samsung Biologics secures record $1.41 billion deal with European client

Samsung Biologics has secured a record $1.41 billion contract with an unnamed European pharmaceutical company, the contract development and manufacturing organization (CDMO) announced in an electronic disclosure Tuesday.

2025-01-14

[NEWS IN FOCUS] Watch out for 'biological missile drugs,' the next big thing in pharma

Antibody-drug conjugates (ADCs) are a growing trend in cancer treatment, with recent breakthroughs attracting significant investment from pharmaceutical and biotech companies worldwide.

2024-01-23

Korean biopharma shoots for the moon at JPM Healthcare Conference

With the global life science industry’s eyes set on San Francisco, Korea’s emerging or rising biopharma companies gathered in the Bay area to join the annual J.P. Morgan Healthcare Conference.

2024-01-11

Celltrion Holdings to go public, establish $76B healthcare fund

Celltrion Holdings will go public, its founder and chairman Seo Jung-jin said, in a bid to establish a massive 100-trillion-won ($75.8-billion) healthcare fund.

2024-01-11

SK Biopharm expects turnaround year with potential 'blockbuster' drug

SK Biopharmaceuticals expects positive cash flow from the epilepsy drug Xcopri, and aims for $2 billion in sales by 2029.

2024-01-10

Samsung Biologics toasts banner year despite biotech slowdown

SAN FRANCISCO — After a record breaking 2023, Samsung Biologics expects both horizontal and vertical growth to continue into this year with upped capacity and expanded modalities.